Investigators: Noah Malmstadt Ph.D.; Robert Seeger M.D. M.S.; Muller Fabbri M.D. Ph.D.; Ambrose Jong Ph. D.; Alan Wayne M.D.
Innovation: develop a new, automated, large-scale device for purifying NK EVs and characterize their ability to kill human ALL and NB cell lines in vitro and cell lines and patient derived xenografts
Clinical significance: new approach to the treatment of cancer that may be effective against a wide array of malignancies in children and adults